Jochen Rüdiger
Immediate non-invasive ventilatory (NIV) support in patients with severe respiratory failure on the emergency ward (ED)- Experience of a 6 months pilot
Jun 1, 2013Background Patients with severe respiratory failure (SRF) are often in need for rapid ventilatory support. Availability of immediate NIV is often limited to the intensive care unit (ICU). We hypothesized that immediate initiation of NIV in the ED is...
Fundamental Research - Jun 1, 2013 - Jan 1, 2015
Completed
Project leader: Rüdiger Jochen, Brutsche Martin
Members: Kleger Gian-Reto, Diethelm Markus, Osterwalder Joseph
Improved adherence to CPAP by Telemetric Support in Newly diagnosed OSAS Patients
Jan 1, 2013Introduction: The acceptance of positive airway pressure therapy (CPAP) within the first month is a critical aspect of successful OSAS therapy. Telemedicine is a novel tool to supervise CPAP use at patient's home. We report 30-day results of a pilot...
Fundamental Research - Jan 1, 2013 - Mar 1, 2013
Completed
Project leader: Schoch Otto, Brutsche Martin
Members: Baty Florent, Niedermann Jolanda, Rüdiger Jochen
The significance of Defensin alpha 4 in the pathophysiology of the adrenal insufficiency in inflammatory lung diseases
Sep 1, 2012The pathophysiology of the adrenal insufficiency of patients with critical diseases remains unclear. In a prior exploratory study investigating patients with exacerbation of chronic obstructive pulmonary disease (COPD), we demonstrated a highly signi...
Fundamental Research - Sep 1, 2012 - Sep 1, 2013
Aborted
Project leader: Rüdiger Jochen
Members: Baty Florent, Bilz Stefan, Lehmann Natalie, Brutsche Martin
The obstructive pulmonary disease outcomes cohort of Switzerland (TOP DOCS): phenotypes and vascular amage in COPD
Jan 1, 2012Prospective cohort study including COPD patients from 6 study centers in Northern Switzerland
Fundamental Research - Jan 1, 2012 - Dec 31, 2015
Automatically Closed
Project leader: Brutsche Martin
Members: Rüdiger Jochen, Burger Barbara, Haider Karin
A multicenter, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension
Oct 1, 2009The primary objective is to demonstrate the effect of ACT-293987 on time to first clinical worsening in patients with pulmonary arterial hypertension (PAH)
Clinical Studies - Oct 1, 2009 - Apr 1, 2013
Aborted
Project leader: Brutsche Martin
Members: Burger Barbara, Haider Karin, Rüdiger Jochen